Search

everythinglearnresearchcommunity

for

Search:↓

The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.

Abrocitinib may effectively treat stubborn alopecia universalis.

The skin microenvironment significantly affects hair growth and loss, offering potential treatment avenues.

Upadacitinib improved multiple immune-related conditions in one patient.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.

Ritlecitinib is generally safe for long-term use, with mostly mild side effects.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.

Ruxolitinib cream effectively targets and treats inflammatory skin diseases.

Topical ruxolitinib cream may help treat frontal fibrosing alopecia.

JAK inhibitors show promise for treating various skin disorders effectively and safely.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.

Upadacitinib effectively treats psoriasiform eczema and some related conditions.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

Upadacitinib effectively treats psoriasis and lichen planus together.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.